Bank of America just raised its EUR/USD forecast
ENGLEWOOD, Colo. - Zynex , Inc. (NASDAQ:ZYXI) shares fell 7.1% after the medical technology company reported fourth-quarter earnings that missed analyst expectations and provided weak guidance for the first quarter of 2025.
The company reported a loss of $0.02 per share for the fourth quarter, falling short of the $0.10 profit analysts had forecast. Revenue came in at $45.98 million, below the consensus estimate of $53.3 million and down 2.8% YoY.
Zynex cited slower payments from certain payers and a temporary payment suspension by Tricare, which represents 20-25% of annual revenue, as reasons for the revenue shortfall. In response, the company is reducing staff by approximately 15% and implementing other cost-cutting measures expected to save about $35 million annually.
For the first quarter of 2025, Zynex projects revenue of at least $30 million, significantly below analyst expectations of $53.457 million. The company also forecasts a loss per share of $0.30 or better, compared to the $0.06 profit analysts were anticipating.
"Our fourth quarter revenue was less than expected," said Thomas Sandgaard, President and CEO of Zynex. "The shortfall was due to slower than normal payments from certain payers and we were recently notified that Tricare has temporarily suspended payments as they review prior claims."
Despite the challenges, Zynex reported full-year 2024 revenue growth of 4% to $192.4 million and net income of $3.0 million, or $0.09 per diluted share. The company generated $12.7 million in cash flow from operations for the year.
Zynex remains focused on expanding its payer relationships and developing new products, including its NiCO laser pulse oximeter, which recently completed clinical trials with positive results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.